 |
3 Diseases |  |
12 Trials |
|
12 Trials |  |
329 News |  |
| «1234 |
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma
Journal, CINV: Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). (Pubmed Central) - Apr 18, 2019
Results suggest that administering oral NEPA closer to initiation of cisplatin administration would provide similar antiemetic efficacy. Prospective clinical validation is required.
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
Clinical, Review, Journal: What is the effect of diet and/or exercise interventions on behavioural compensation in non-exercise physical activity and related energy expenditure of free-living adults? A systematic review. (Pubmed Central) - Apr 11, 2019
Although these findings do not support the hypothesis that prescribed diet and/or exercise results in decreased NEAT and NEPA in healthy adults, the underpowered trial design and the lack of state-of-the-art methods may limit these conclusions. Future studies should explore the impact of weight-loss magnitude, energetic restriction degree, exercise dose and participant characteristics on NEAT and/or NEPA.
- || Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
So well deserved. Stu had a major impact on my decision to come to UAB. And he's from #NEPA! Dean's Excellence Award winner profile: Stuart Frank, M.D. https://t.co/idqlrV6AFi (Twitter) - Apr 11, 2019
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
Clinical, P3 data, Journal, CINV: A Randomized Phase 3 Study Evaluating the Efficacy of Single-dose NEPA, a Fixed Antiemetic Combination of Netupitant and Palonosetron, Versus an Aprepitant Regimen for Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC). (Pubmed Central) - Apr 3, 2019
...NEPA, a fixed combination of a highly selective NK1 receptor antagonist, netupitant (300 mg), and the pharmacologically distinct 5-HT3RA, palonosetron (PALO 0.50 mg), has shown superior CINV prevention compared with PALO in cisplatin and anthracycline/cyclophosphamide-based settings...All patients also received oral dexamethasone (DEX) on days 1-4...NEPA was well tolerated with a similar safety profile to APR/GRAN. In this first study comparing NK1RA regimens and DEX, NEPA administered only on day 1 was non-inferior to a 3-day oral APR/GRAN regimen in preventing CINV associated with HEC.
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
New P2 trial: GIM15-NEPA: NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov) - Mar 5, 2019
P2, N=150, Completed, Sponsor: Consorzio Oncotech
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: AKY15-HK-301_NEPA Study (clinicaltrials.gov) - Feb 22, 2019
P2, N=60, Recruiting, Sponsor: Chinese University of Hong Kong
In this first study comparing NK1RA regimens and DEX, NEPA administered only on day 1 was non-inferior to a 3-day oral APR/GRAN regimen in preventing CINV associated with HEC. Trial primary completion date: Dec 2018 --> Dec 2019
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
New P4 trial, HEOR: Comparative Effectiveness of AKYNZEO (clinicaltrials.gov) - Feb 6, 2019
P4, N=426, Recruiting, Sponsor: VIFORFRANCE
- ||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Trial completion: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (clinicaltrials.gov) - Jan 8, 2019
P3b, N=404, Completed, Sponsor: Helsinn Healthcare SA
Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Completed
- | Enrollment open, Real-world evidence, Real-world: EVOLVE_CINV: Observational Study on the Use of Akynzeo (clinicaltrials.gov) - Oct 24, 2018
P=N/A, N=200, Recruiting, Sponsor: Purdue Pharma, Canada
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Enrollment open: Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin (clinicaltrials.gov) - Oct 17, 2018
P2/3, N=80, Recruiting, Sponsor: Christina Ruhlmann
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
Trial completion date, Trial primary completion date: PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting (clinicaltrials.gov) - Aug 22, 2018
P2, N=92, Recruiting, Sponsor: Helsinn Healthcare SA
Not yet recruiting --> Recruiting Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019
- |||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Enrollment open: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (clinicaltrials.gov) - Apr 12, 2018
P3b, N=400, Recruiting, Sponsor: Helsinn Healthcare SA
Trial completion date: Apr 2018 --> Jan 2019 | Trial primary completion date: Apr 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
Enrollment open, Trial completion date, Trial primary completion date: Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov) - Mar 14, 2018
P3, N=800, Recruiting, Sponsor: Gary Morrow
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- ||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Trial initiation date: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (clinicaltrials.gov) - Mar 8, 2018
P3b, N=400, Not yet recruiting, Sponsor: Helsinn Healthcare SA
Not yet recruiting --> Recruiting | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Dec 2021 --> Dec 2022 Initiation date: Feb 2018 --> Mar 2018
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
Trial initiation date: Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov) - Mar 3, 2018
P3, N=800, Not yet recruiting, Sponsor: Gary Morrow
Initiation date: Feb 2018 --> Mar 2018 Initiation date: Feb 2018 --> Mar 2018
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open, Trial initiation date: AKY15-HK-301_NEPA Study (clinicaltrials.gov) - Mar 2, 2018
P2, N=60, Recruiting, Sponsor: Chinese University of Hong Kong
Initiation date: Feb 2018 --> Mar 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
New P3 trial: A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (clinicaltrials.gov) - Jan 19, 2018
P3b, N=400, Not yet recruiting, Sponsor: Helsinn Healthcare SA
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P2 trial: AKY15-HK-301_NEPA Study (clinicaltrials.gov) - Dec 29, 2017
P2, N=60, Not yet recruiting, Sponsor: Chinese University of Hong Kong
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
New P3 trial: Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (clinicaltrials.gov) - Dec 7, 2017
P3, N=800, Not yet recruiting, Sponsor: Gary Morrow
- | Journal: Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. (Pubmed Central) - Oct 20, 2017
Aprepitant has not shown consistent superiority over a two-drug (ondansetron-dexamethasone) combination in nausea control after cisplatin- or anthracycline-cyclophosphamide (AC)-based highly emetogenic chemotherapy (HEC)...The potential impact of the new NK1RAs rolapitant and netupitant (oral fixed combination with palonosetron, as NEPA) in CIN prophylaxis is discussed...Recently, NK1RAs have been challenged by olanzapine, with olanzapine showing superior efficacy in nausea prevention after HEC. Fixed antiemetic combinations (such as NEPA) or new antiemetics with a long half-life that may be given once per chemotherapy cycle (rolapitant or NEPA) may improve patient compliance with antiemetic treatment.
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai
Journal: NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. (Pubmed Central) - Oct 13, 2017
Fixed antiemetic combinations (such as NEPA) or new antiemetics with a long half-life that may be given once per chemotherapy cycle (rolapitant or NEPA) may improve patient compliance with antiemetic treatment. NEPA, a convenient, guideline-consistent, fixed antiemetic combination is effective and safe over multiple cycles of chemotherapy.
- |||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
Enrollment open: PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting (clinicaltrials.gov) - Sep 7, 2017
P2, N=92, Recruiting, Sponsor: Helsinn Healthcare SA
NEPA, a convenient, guideline-consistent, fixed antiemetic combination is effective and safe over multiple cycles of chemotherapy. Not yet recruiting --> Recruiting
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Enrollment open, CINV: Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant (clinicaltrials.gov) - Aug 18, 2017
P2, N=43, Recruiting, Sponsor: OHSU Knight Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
New P2 trial: PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting (clinicaltrials.gov) - Jul 2, 2017
P2, N=92, Not yet recruiting, Sponsor: Helsinn Healthcare SA
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Enrollment open: Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer (clinicaltrials.gov) - May 8, 2017
P2/3, N=42, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai
Review, Journal: NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. (Pubmed Central) - Apr 12, 2017
Not yet recruiting --> Recruiting Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK.
- | Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
New P2 trial, CINV: Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant (clinicaltrials.gov) - Mar 31, 2017
P2, N=43, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- ||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
New P2/3 trial: Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer (clinicaltrials.gov) - Feb 2, 2017
P2/3, N=42, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka
New P2 trial: Combination of Netupitant and Palonosetron (Akynzeo (clinicaltrials.gov) - Jan 3, 2017
P2, N=50, Not yet recruiting, Sponsor: University of California, San Diego
- ||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Trial completion: A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Sep 8, 2016
P3, N=405, Completed, Sponsor: Helsinn Healthcare SA
Despite study limitations (study setting, time horizon, utility measure), the results suggest NEPA is cost effective for preventing CINV associated with HEC and MEC in the UK. Recruiting --> Completed
- |||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
Enrollment open: A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Dec 3, 2015
P3, N=400, Recruiting, Sponsor: Helsinn Healthcare SA
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica, Akynzeo IV (fosnetupitant/palonosetron) / Helsinn
New P3 trial: A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Aug 6, 2015
P3, N=400, Not yet recruiting, Sponsor: Helsinn Healthcare SA
- ||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Trial completion: A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Jan 15, 2013
P3, N=413, Completed, Sponsor: Helsinn Healthcare SA
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||||| Akynzeo oral (netupitant/palonesteron FDC) / Helsinn, Roche, Otsuka, Mundipharma, Immedica
Trial completion, Combination therapy: An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting (clinicaltrials.gov) - Jan 15, 2013
P3, N=1455, Completed, Sponsor: Helsinn Healthcare SA
Recruiting --> Completed Recruiting --> Completed